Skip to content
Screener

Agios Pharmaceuticals AGIO Q4 2025 Annual earnings

Reported February 12, 2026 · Before market open

Revenue$20.0MBeat by $7.9M
EPS-$1.85Beat by $0.12
Revenue estimate$12.1M
EPS estimate-$1.97

Next report

Oct 29, 2026 (in a month)
Revenue estimate$53.8M
EPS estimate-$1.21

Financials

Q4 2025

Income statement

See full
Revenue$20.0M+86.1%
Gross profit$18.1M+91.0%
Operating income-$121.6M+2.8%
Net income-$108.0M—
EPS (diluted)-$1.85—

Balance sheet

See full
Cash & equivalents$89.1M+16.9%
Total debt$40.2M-29.4%
Total equity$1.2B-22.6%
Total assets$1.3B-22.0%

Cash flow

See full
Operating cash flow-$96.2M+27.8%
CapEx$1.1M+15.8%
Free cash flow-$97.3M+27.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.59B-15.3%
Enterprise value$1.54B-17.1%
P/S29.4×-22.0×

Profitability

See full
Gross margin88.3%-0.3pp
Operating margin-873.9%-175pp
Net margin-764%—
FCF margin-698.3%-181pp

Returns & leverage

See full
Return on equity-30.2%—
Debt / equity0×0.0×
Current ratio11.5×-0.4×

FAQ

When did Agios Pharmaceuticals report Q4 2025 earnings?
Agios Pharmaceuticals (AGIO) reported Q4 2025 earnings on February 12, 2026 before market open.
What were Agios Pharmaceuticals's Q4 2025 revenue and EPS?
Agios Pharmaceuticals reported revenue of $20.0M and eps of $-1.85 for Q4 2025.
Did Agios Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $12.1M by $7.9M. EPS beat the consensus estimate of $-1.97 by $0.12.
How did Agios Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 86.1% from $10.7M a year earlier and eps declined 6.3% from $-1.74.
Where can I find Agios Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001439222-26-000023) and the 10-K periodic report (0001439222-26-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.